Life expectancy in thymidine kinase 2 deficiency (TK2d) varies widely and is closely tied to age at symptom onset. Over time the rare disorder weakens skeletal muscles, including those needed for breathing and movement, which can lead to an early death.
While studies provide life expectancy ranges for each type of TK2d, it’s important to remember that there is no way to predict how long any individual will live with the condition. Additionally, these estimates come largely from historical and early-treatment data; emerging therapies are expected to shift the outlook in the coming years.
Life expectancy for infantile-onset TK2d
When symptoms begin before the first birthday, the disease typically follows a rapid and severe course. Data suggests a median survival of roughly one year after the beginning of symptoms, which often include muscle weakness, feeding difficulties and trouble breathing.
Many children die within one to two years of onset, most often due to respiratory failure. The early and profound involvement of breathing muscles is the key factor shaping prognosis in this group.
Learn more about TK2d prognosis
Life expectancy for childhood-onset TK2d
Symptoms that begin between ages 1 and 12 usually progress more slowly but still remain life-limiting. Because of progressive muscle weakness, many children with this type of TK2d will need to use a wheelchair. Breathing difficulties may also require ventilator support.
While life expectancy varies, many children survive through adolescence, with respiratory complications remaining the main driver of mortality. However, the course can vary significantly between individuals, with some living well into adulthood.
Life expectancy for late-onset TK2d
Late-onset disease, including adult-onset cases, is associated with the longest survival. Symptoms progress gradually over time, with limb and respiratory muscle weakness developing over decades. Individuals may maintain mobility and independence for many years before requiring assistive mobility devices and respiratory support.
Most people with this type of TK2d live 20 to 30 years after symptom onset, with respiratory failure as the primary cause of death.
Treatment advances may change these numbers
In the coming years, the figures above are likely to be reshaped by treatment advances. Nucleoside therapy has shown the ability to slow disease progression, improve muscle and respiratory function and reduce mortality risk in early studies. Gene therapy approaches are also moving through research and clinical development.
With more research, these treatments may become more widely available and future patients may live significantly longer than current estimates suggest.
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.